Syndax Q2 2023 Earnings Report
Key Takeaways
Syndax Pharmaceuticals reported its financial results for Q2 2023, highlighting positive data from the AGAVE-201 trial of axatilimab and progress with the AUGMENT-101 trial of revumenib. Two U.S. registrational filings are expected by the end of 2023.
Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD.
Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023.
Two U.S. registrational filings expected by the end of 2023.
Cash, cash equivalents, short- and long-term investments of $418.3 million as of June 30, 2023.
Syndax
Syndax
Forward Guidance
The Company expects research and development expenses to be $39 to $43 million and total operating expenses to be $57 to $62 million for the third quarter of 2023. For the full year of 2023, the Company continues to expect research and development expenses to be $160 to $175 million and total operating expenses to be $225 to $240 million.